Related Experiment Video
Updated: Apr 5, 2026

Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
Parkinson disease: Laying the foundations for disease-modifying therapies in PD
Patrik Brundin1, Richard Wyse2
1Van Andel Research Institute, Translational Parkinson's Disease Research, Center for Neurodegenerative Science, 333 Bostwick Avenue NE, Grand Rapids, MI 49503, USA.
Abstract:
The results of a futility trial, which used the PPAR-γ receptor agonist pioglitazone in an attempt to modify disease progression in Parkinson disease, do not support initiation of further trials. However, although this trial was well designed and conducted, we question whether it is time to fully shut the door on pioglitazone.
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease: Overview
Alzheimer's Disease: Treatment
Drug Therapy
Antianxiety Medications
Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring: Overview and Classification

